LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Public Assessment Report
Scientific discussion

Olopatadin Orifarm
(olopatadine hydrochloride)

SE/H/2075/01/DC

This module reflects the scientific discussion for the approval of Olopatadin Orifarm. The procedure was finalised on 2021-12-16. For information on changes after this date please refer to the module 'Update'.

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se

I. INTRODUCTION

Based on the review of the quality, safety and efficacy data, a marketing authorisation has been granted for Olopatadin Orifarm, 1 mg/ml, Eye drops, solution.

The active substance is olopatadine hydrochloride, olopatadine. A comprehensive description of the indication and posology is given in the SmPC.

For recommendations to the marketing authorisation not falling under Article 21a/22a/22 of Directive 2001/83/EC and conditions to the marketing authorisation pursuant to Article 21a/22a/ 22 of Directive 2001/83/EC to the marketing authorisation, please see section VI.

The application for Olopatadin Orifarm, 1 mg/ml, eye drops, solution, is submitted according to Article 10(3) of Directive 2001/83/EC. The applicant, Orifarm Generics A/S applies through the Decentralised Procedure with Sweden acting as reference member state (RMS) and DK as concerned member states (CMS).

The reference medicinal product chosen for the purposes of establishing the expiry of the data protection period is Opatanol, 1 mg/mL, eye drops, solution, authorised in the EU since 2002, with Novartis Europharm Ltd. as marketing authorisation holder.

According to the application form and a check of the Community Register of orphan medicinal products there is no medicinal product designated as an orphan medicinal product for a condition relating to the indication proposed in this application.

II. QUALITY ASPECTS

II.1 Drug Substance

The structure of the drug substance has been adequately proven and its physico-chemical properties are sufficiently described.

The manufacture of the drug substance has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.

The drug substance specification includes relevant tests and the limits for impurities and degradation products have been justified. The analytical methods applied are suitably described and validated.

Stability studies confirm the retest period.

II.2 Medicinal Product

The medicinal product is formulated using excipients listed in section 6.1 in the Summary of Product Characteristics.

The manufacturing process has been sufficiently described and critical steps identified.

The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.

Stability studies have been performed and data presented support the shelf life and special precautions for storage claimed in the Summary of Product Characteristics, sections 6.3 and 6.4.

III. NON-CLINICAL ASPECTS

Pharmacodynamic, pharmacokinetic and toxicological properties of olopatadine are well known. As olopatadine is a widely used, well-known active substance, no further studies are required and the applicant provides none. Overview based on literature review is, thus, appropriate.

The non-clinical overview on the pre-clinical pharmacology, pharmacokinetics and toxicology is adequate.

Environmental Risk Assessment (ERA)
Since Olopatadin Orifarm is intended for substitution with marketed products containing the same active substance, it will not lead to an increased exposure to the environment. An environmental risk assessment is therefore not deemed necessary.

There are no objections to approval of Olopatadin Orifarm from a non-clinical point of view.

IV. CLINICAL ASPECTS

No clinical studies have been conducted to support the application. The applicant refers to the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1/Corr**) to justify an exemption from conducting a bioequivalence study. The exemption is acceptable from a clinical point of view, since essential similarity with the originator product *"Opatanol 1 mg/ml eye drops solution"* can be reasonably assumed given the same pharmaceutical form with the same quantitative and qualitative composition of the product and because equivalence has been shown based on quality data.

The justification for a bio-waiver is therefore acceptable, also in view of the topical pharmacological effect of the product at the site of administration.

Pharmacokinetics
The applicant presents in the Clinical Overview characteristics of absorption, distribution, metabolism, excretion and pharmacokinetics in special populations of orally and ocular administered olopatadin. This is deemed acceptable.

Pharmacodynamics/Clinical efficacy/Clinical safety
No new studies on pharmacodynamics, clinical efficacy or clinical safety have been submitted. Since essential similarity with the reference product can be reasonably assumed and because equivalence has been shown based on quality data, additional data is not considered necessary.

Risk Management Plan
The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Olopatadin Orifarm.

Safety specification

Important identified risks	None
Important potential risks	None
Missing information	None

The Applicant has proposed a list of safety concern that is empty, and this is in accordance with the intention of GVP V (rev 2). And since there is no need for additional pharmacovigilance activities nor additional risk minimization measures for the safety concerns, it is agreed that the list of safety concern could be empty.

Pharmacovigilance Plan
Routine pharmacovigilance is suggested, and no additional pharmacovigilance activities are proposed by the applicant, which is endorsed.

Risk minimisation measures
Routine risk minimisation is suggested, and no additional risk minimisation activities are proposed by the applicant, which is endorsed.

Summary of the RMP
The submitted Risk Management Plan, version 1.0 with DLP 26 June 2020 and signed 26 June 2020 is considered acceptable.

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the RMS
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time, but via different procedures.

V. USER CONSULTATION

A user consultation with target patient groups on the package information leaflet (PL) has been performed on the basis of a bridging report making reference to Olopatadine UNIMED PHARMA 1 mg/ml eye drops, solution, SK/H/0202/001/DC, regarding the content and Kaliumklorid Orifarm 750 mg depottabletter, DK/H/2347/001, regarding the layout.
The bridging report submitted by the applicant has been found acceptable.

VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

The quality of the hybrid product, Olopatadin Orifarm, is found adequate. There are no objections to approval of Olopatadin Orifarm, from a non-clinical and clinical point of view.
The application contains an adequate review of published clinical data. A bio-waiver is justified based on essential similarity as well as comparative quality attributes compared with the reference product. Therefore, no clinical studies have been conducted nor deemed necessary to support the application.

The product information is acceptable. The benefit/risk is considered positive, and the application is therefore recommended for approval.

List of recommendations not falling under Article 21a/22a/22 of Directive 2001/83/EC in case of a positive benefit risk assessment

N/A

List of conditions pursuant to Article 21a/22a or 22 of Directive 2001/83/EC

N/A

VII. APPROVAL

The decentralised procedure for Olopatadin Orifarm, 1 mg/ml, Eye drops, solution was positively finalised on 2021-12-16.

LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Public Assessment Report – Update

Procedure number*	Scope	Product Information affected (Yes/No)	Date of end of procedure	Approval/ non approval	Summary/ Justification for refuse

*Only procedure qualifier, chronological number and grouping qualifier (when applicable)

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se